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Erythropoietin (Epo) is an indispensable erythropoietic hormone primarily produced
from renal Epo-producing cells (REPs). Epo production in REPs is tightly regulated
in a hypoxia-inducible manner to maintain tissue oxygen homeostasis. Insufficient
Epo production by REPs causes renal anemia and anemia associated with chronic
disorders. Recent studies have broadened our understanding of REPs from prototypic
hypoxia-responsive cells to dynamic fibrogenic cells. In chronic kidney disease, REPs
are the major source of scar-forming myofibroblasts and actively produce fibrogenic
molecules, including inflammatory cytokines. Notably, myofibroblast-transformed REPs
(MF-REPs) recover their original physiological properties after resolution of the disease
insults, suggesting that renal anemia and fibrosis could be reversible to some extent.
Therefore, understanding the plasticity of REPs will lead to the development of novel
targeted therapeutics for both renal fibrosis and anemia. This review summarizes the
regulatory mechanisms how hypoxia-inducible Epo gene expression is attained in health
and disease conditions.
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Introduction
Erythropoietin (Epo) is an indispensable erythropoietic glycoprotein hormone that induces red
blood cell production (Haase, 2010; Bunn, 2013; Suzuki, 2015). Circulating Epo concentration
is dynamically altered by the presence of hypoxia or anemia; up to 1000-fold increase in
the circulating Epo concentration is reported in anemic patients (Bunn, 2013). Epo exerts its
erythropoietic function through binding to Epo receptor (EpoR) (Remy et al., 1999). The EpoR
expression level in erythroid progenitor cells is dependent on their differentiation stage; EpoR
is most highly expressed in late-stage erythroid progenitors to early erythroblasts (Suzuki et al.,
2003; Yamazaki et al., 2013). The Epo–EpoR signaling primarily mediates survival signaling in these
progenitor cells and prevents their apoptosis, causing proliferation and differentiation, and thereby
activating erythropoiesis (Wu et al., 1995).
Regarding its application to medicine, Epo represents a prototypical success of molecular
biology. The presence of Epo was first suggested in the nineteenth century based on the high
blood viscosity of people living in or returning from high altitude areas (Koury, 2005; Bunn,
2013). Experimentally, the presence of Epo as an erythropoietic humoral factor was discovered
in the early twentieth century due to the erythropoietic property of serum from phlebotomized
rabbits. Most notably, in 1977, Miyake et al. purified Epo from 2550 liters of urine from patients of
aplastic anemia and determined its amino acid sequence (Miyake et al., 1977). Based on this finding,
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the human Epo genes were cloned in 1985 (Jacobs et al., 1985;
Lin et al., 1985). Then, recombinant human Epo (rHuEpo) was
successfully used to treat anemic patients with end-stage renal
diseases (ESRD) (Bunn, 2013). Furthermore, studies on Epo
gene regulation led to the identification of hypoxia-inducible
transcription factors (HIFs) and hypoxia response elements
(HREs) as the HIF-binding consensus sequence on genome
(Semenza et al., 1991b), and to the current understanding of
the molecular mechanisms of cellular adaptation to hypoxia
(Semenza, 2011; Ratcliffe, 2013).
In past decades, many researchers have made rigorous efforts
to identify erythropoietin-producing cells in kidneys; however, a
uniform understanding of which cells produce Epo in kidneys
was not established until the era of genetically modified mice
(Suzuki et al., 2007). Using gene targeting and bacterial artificial
chromosome (BAC) transgenic methods, we identified nearly all
of interstitial fibroblast-like cells in the cortex and outer medulla
to be renal erythropoietin-producing cells (REPs) (Obara et al.,
2008; Pan et al., 2011; Yamazaki et al., 2013). Furthermore,
interests in REPs have markedly increased by the evidence
showing the crucial link between fibrosis and anemia via the
loss of Epo-producing ability of myofibroblast-transformed REPs
(MF-REPs) (Maxwell et al., 1997; Asada et al., 2011; Souma
et al., 2013). Importantly, this direct link indicates that renal
fibrosis and anemia could be simultaneously treated by targeting
or regulating the cellular properties of REPs. In this review, we
provide a summary of recent lines of evidence regarding the
role of REPs in health and disease and discuss future research
directions for regulating REP functions to treat both fibrosis and
anemia.
Identification of Renal
Erythropoietin-Producing Cells
To identify Epo-producing cells in the kidneys, in situ
hybridization and/or immunohistochemistry have been utilized
to detect Epo in tissue sections. However, these strategies
have limited sensitivity and specificity for detecting Epo,
hampering the establishment of a consensus as to which
cells produce Epo. By using a transgenic mouse technology,
SV40 T antigen cDNA was integrated into the Epo gene
locus to identify renal Epo-producing cells (REPs) with
anti-T antigen antibodies (Maxwell et al., 1993), and the
results showed that renal fibroblasts are the top candidates
among the proposed Epo-producing cells including tubular
epithelial cells, glomerular mesangial cells, and interstitial
fibroblasts.
To unequivocally determine the identity of REPs, we have
utilized two complimentary strategies, BAC transgenic mice and
green fluorescent protein (GFP) reporter knock-in mice (Obara
et al., 2008; Pan et al., 2011). The BAC transgenic mouse lines
(Tg-EpoGFP) harbor transgene constructs, which direct GFP
expression under the control of the 180-kb regulatory region
around the mouse Epo gene, and label Epo-producing cells by
GFP expression with high sensitivity. The other strategy using
a genetically modified mouse line (KI-EpoGFP, EpoGFP/wt), in
which the GFP cDNA is knocked-in to the endogenous Epo
gene, assures a higher specificity than the Tg-EpoGFP strategy
because the GFP expression in the knock-in mice is directed by
endogenous Epo gene regulation. Only a few renal interstitial cells
are labeled by both strategies under normal conditions, whereas
GFP-positive cells robustly emerge and increase in the kidneys
under anemic or hypoxic stress. These GFP-positive cells in the
interstitium are fibroblast-like cells expressing neural genes [e.g.,
microtubule-associated protein 2 (Map2), nerve growth factor
receptor (Ngfr), and neurofilament light peptide (Nefl)]. We
named these cells renal erythropoietin-producing cells, or REPs
(Suzuki et al., 2007; Obara et al., 2008).
Epo Gene Modification for Further
Analyses of REPs
Epo-knockout mice die at approximately embryonic day 12.5
(E12.5) due to severe anemia (Wu et al., 1995), hampering
the analyses of Epo gene function in adults. We assumed that
the embryonic lethality of Epo-null mice could be rescued by
transgenic Epo gene expression in the livers of embryos because
hepatocytes are the Epo-producing cells at the lethal time point
(Suzuki et al., 2011). To this end, we have utilized the knowledge
regarding Epo gene regulation; i.e., the proximal downstream
region of the Epo gene transcription end site (EpoHE, hepatic
enhancer) is sufficient for Epo gene expression from hepatocytes,
but is dispensable for renal Epo gene expression (Suzuki et al.,
2011). An 8-kb Epo transgene (Tg-Epo3.3) containing EpoHE but
not the kidney regulatory elements has been constructed. This
transgene successfully rescues the embryonic lethality of Epo-
null mice (EpoGFP/GFP) (Yamazaki et al., 2013). In the transgene-
rescued mice (named as Inherited Super-Anemic Mice, ISAM;
EpoGFP/GFP:Tg-Epo3.3), Epo is mainly produced in their liver,
and the plasma Epo concentrations are repressed to undetectable
levels by the weaning age, which is the ontogenetic time point
at which the Epo-producing site switches from the liver to the
kidney. ISAM develop adult onset severe chronic anemia due
to defect in renal Epo production, and Epo-producing cells are
efficiently labeled with GFP expression from the Epo gene locus
in adult ISAM kidneys (Yamazaki et al., 2013).
The numbers of GFP-expressing REPs are markedly higher in
ISAM with chronic severe anemia than those of Tg-EpoGFP or
KI-EpoGFPmice with bleeding-induced acute anemia (Yamazaki
et al., 2013). Thus, it appears that the EpoGFP-expressing
cells represent a small portion of the total REPs. To identify
the total REPs, we have conducted fate-tracking assays of
cells with a history of Epo production using newly generated
Tg-EpoCre mice in which the Cre-recombinase is expressed
under the regulation of the 180-kb transgene containing the
Epo gene regulatory region (Souma et al., 2013; Yamazaki
et al., 2013). To detect EpoCre-labeled cell lineages, we have
utilized the R26RtdTomato mouse line in which cells that
have expressed Cre at least once are marked by tdTomato red
fluorescence. When EpoCre transgene expression is enhanced
by chronic severe anemia in ISAM (ISAM:R26RtdTomato:Tg-
EpoCre, ISAM-REC), tdTomato fluorescence is detected in
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almost all fibroblast-like interstitial cells (PDGFRβ+CD73+ cells)
in the cortex and outer medulla (both the outer stripe and the
inner stripe) (Figure 1). The results indicate that cells capable of
producing Epo (total REPs) are far more abundant in kidneys
than we previously expected in Tg-EpoGFP mice. Interestingly,
we have observed REPs around the peritubular capillaries, but
not in the regions surrounding the larger vessels (Figure 1).
Furthermore, in ISAM-REC kidneys, approximately 10% of
tdTomato-positive cells express EpoGFP (ON-REPs), indicating
that most REPs (OFF-REPs) are resting from Epo production
even under severe anemic conditions (Figure 1) (Yamazaki et al.,
2013; Souma et al., 2013).
Regulatory Mechanisms Governing Epo
Synthesis
The balance between oxygen supply and demand precisely
controls renal Epo production. A salient physiological study
using isolated rat kidneys with hypoxic perfusate shows that
renal Epo secretion is regulated by tissue oxygen tension (Pagel
et al., 1990). Distant organs, such as skin have been found
to participate in regulation of renal Epo synthesis through
sensing a hypoxic atmosphere (Boutin et al., 2008). Recently,
Dimke et al. demonstrated that the importance of the renal
oxygen levels for renal Epo gene expression using a mouse
model with tubular-specific Vegfa (vascular endothelial growth
factor a) gene deletion. In this mouse model, the kidney has
scarce vascularization, resulting in renal hypoxia, increased
Epo secretion, and severe polycythemia (Dimke et al., 2015),
indicating that the oxygen supply in the kidneys, but not in other
organs or tissues, is the most important factor to determine renal
Epo synthesis.
Induction of hypoxia/anemia widely spread the distribution
of currently Epo-producing cells (ON-REPs: defined by
EpoGFP expression) from the juxta-medullary region, which
is physiologically hypoxic, to the entire cortex (Koury et al.,
1989; Eckardt et al., 1993; Obara et al., 2008; Souma et al., 2013;
Yamazaki et al., 2013). Interestingly, the ratio of ON-REPs to the
total REPs in the kidney correlates well with plasma Epo levels,
indicating that renal Epo secretion is regulated by “ON–OFF
switch” for Epo-gene expression in each REP in a hypoxia-
inducible manner (Figure 2). In other words, the conversion of
OFF-REP to ON-REP is governed by transcriptional control of
the Epo gene, which is primarily regulated by HIF transcription
factors (Haase, 2010; Suzuki, 2015).
Understanding of the Epo gene regulation has been advanced
by the discovery of Epo-producing hepatoma cell lines (Hep3B
and HepG2) (Goldberg et al., 1987). Analyses of these cells led
to the discovery of HIF proteins and their binding sequences,
HREs (Figure 3) (Semenza et al., 1991b). In order to understand
renal Epo gene regulation, transgenic mouse lines with different
regulatory regions have been generated. For instance, EpoHE
containing an HRE is proved to be necessary and sufficient
to direct hepatic Epo gene expression in vivo (Suzuki et al.,
2011). However, this enhancer is dispensable for renal Epo
gene expression, indicating that other cis-elements direct renal
FIGURE 1 | REPs are peri-capillary CD73-positive fibroblast-like cells.
A kidney section from ISAM-REC (ISAM:R26RtdTomato:Tg-EpoCre) shows
ON-REPs expressing EpoGFP (arrowheads, positive for both green and red) in
the total REP population (positive for tdTomato fluorescence, red). The nuclei
are stained by DAPI (blue). A kidney section from ISAM-REC shows that REPs
or CD73-positive fibroblasts are distributed in peri-capillary interstitial spaces
but not in peri-arterial interstitial areas of the kidneys. DAPI (blue) is used for
nuclear staining in the merged image. Abbreviations: A, artery; V, vein. Scale
bar, 100µm.
Epo production (Figure 3). EpoHE also contains a direct repeat
sequence that is considered a binding site for hepatic nuclear
factor 4 (HNF4) and/or retinoid X receptor (RXR); together with
HIFs, these factors synergistically regulate liver-specific, hypoxia-
inducible Epo gene expression (Galson et al., 1995; Makita et al.,
2001).
One of the important lingering questions about Epo gene
regulation is the location and characteristics of the regulatory
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FIGURE 2 | ON–OFF regulation of Epo synthesis in REPs. (A) Oxygen
deficiency turns OFF-REPs into ON-REPs by turning on “Epo gene switch.”
(B) REPs are primarily in the “OFF” state (OFF-REPs, brown dots) under
normal oxygen conditions. Under acute anemic conditions, some clusters of
OFF-REPs turn into ON-REPs (green dots). The distribution of ON-REPs
extends toward hypoxic cortical areas (orange). Strikingly, most OFF-REPs
turn into ON-REPs under chronic anemia. This recruitment of ON-REPs
determines the total amount of Epo secreted by the kidneys.
regions for renal Epo gene expression. It has been surmised that
an essential regulatory region may lie far upstream from the
transcription start site (−14 to −6 kb; Figure 3) (Semenza et al.,
1991a; Madan et al., 1995; Suzuki et al., 2013). We also have
utilized a series of BAC transgenic reporter lines that direct GFP
expression from the transgenic Epo locus, and the regulatory
region for renal Epo gene expression has been narrowed down to
the region from −17 to +15 kb (Obara et al., 2008; Suzuki et al.,
2013).
The Epo gene promoter lacks the typical TATA box, but
has a negative regulatory element with a GATA box (Imagawa
et al., 1991). By mutating the GATA box in EpoGFP transgene
constructs, the GATA box is proved to be not necessary for
inducible Epo gene expression in either REPs or hepatocytes
(Obara et al., 2008). However, the GATA box is turned out to
be indispensable for repressing ectopic Epo gene expression in
epithelial lineage cells, including distal tubular cells, bronchial
epithelial cells, and cholangiocytes. In renal distal tubular
cells, the GATA box is occupied by GATA transcription
factors. In this manner, the GATA box contributes to the
tissue-specific Epo gene expression (Figure 3) (Obara et al.,
2008).
Of the transcription factors interacting with these Epo gene
regulatory regions, HIFs play the central role in hypoxia-
inducible Epo gene expression (Haase, 2010; Suzuki, 2015). HIFs
are heterodimeric complexes comprising one α subunit (HIF1α,
HIF2α, and HIF3α) and one β subunit (HIF1β, also known
as ARNT) (Semenza, 2011; Ratcliffe, 2013). Under oxygen-
replete conditions, the proline residues of HIFα subunits are
FIGURE 3 | Overview of Epo gene transcriptional regulation. Under
oxygen-replete conditions, PHDs hydroxylate HIF2α proteins, leading to
pVHL-mediated ubiquitination and degradation of HIF2α. Under
oxygen-depleted condition, PHDs are inactivated, and HIF2α escapes
degradation. The HIF2α–HIF1β heterodimer activates Epo gene transcription
by binding to the HRE. The functional HRE for hepatic Epo gene expression
(EpoHE) is in the proximal downstream region of the transcription end site,
whereas a kidney enhancer has been suggested to be located in a region far
upstream of the transcription start site. GATA factors constitutively suppress
ectopic Epo gene expression in epithelial lineage cells by binding to the
promoter GATA sequence.
hydroxylated by HIF prolyl hydroxylases (or prolyl hydroxylase
domain proteins, PHDs: PHD1, PHD2, and PHD3), leading
to their proteasomal degradation via pVHL (von Hippel
Lindau protein)-mediated ubiquitination (Figure 3) (Tanimoto
et al., 2000). Under oxygen-deficient conditions, the enzymatic
activities of PHDs are inhibited, and HIFα proteins escape from
degradation. Stable HIFα proteins dimerize with HIF1β, and the
heterodimeric complexes bind to HRE in regulatory regions of
target genes, including Epo (Figure 3). PHD2 and HIF2α are
the most important factors among those related to PHD-HIF
signaling in the renal Epo production (Table 1) (Souma et al., in
press).
In addition to PHDs, another HIF-hydroxylase, FIH-1 (factor
inhibiting HIF-1), is involved in the cellular responses to hypoxia
(Mahon et al., 2001). FIH-1 negatively regulates HIF-dependent
transactivation by inhibiting CREB-binding protein (CBP)/p300
recruitment to HIFα via the asparaginyl hydroxylation of HIFα
proteins. The asparaginyl hydroxylation is more resistant to
suppression by hypoxia than the prolyl hydroxylation (Tian
et al., 2011). FIH-1-dependent hydroxylation is more prone
to be inhibited by oxidative stresses than by hypoxic stresses
(Masson et al., 2012). Consistent with these findings, the
systemic knockout of FIH-1 does not result in defects in
the Epo gene regulation directly (Table 1) (Zhang et al.,
2010).
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TABLE 1 | Summary of gene targeting studies of hypoxia-related factors
on renal Epo gene regulation.
Deleted factor Effects on renal
Epo gene
expression
References
HIF1α Inducible KO in
adult: no change
Gruber et al.,
2007
HIF2α Inducible KO in
adult: decrease
Kidney-specific KO:
decrease
Gruber et al.,
2007;
Rankin et al.,
2006
PHD1 and PHD3 Systemic double
KO: no change
Takeda et al.,
2008
PHD2 Inducible KO in
adult: increase
REP-specific KO:
increase
Takeda et al.,
2008;
Souma et al., in
press
pVHL Kidney-specific KO:
increase
Rankin et al.,
2006
KO, knockout.
REPs as Major Contributors to Renal
Fibrosis
All chronic nephropathies progress with tubular atrophy and
interstitial fibrosis along with the relative loss of Epo production
(Quaggin and Kapus, 2011). While fibrosis is an essential
biological process for repairing tissue injuries, uncontrolled and
persistent injuries lead to sustained fibrogenesis, followed by
destruction of tissue architecture and organ failure (Quaggin and
Kapus, 2011; Friedman et al., 2013). Therefore, the identification
of therapeutics controlling the pathological fibrogenic response
would be beneficial for many devastating diseases, such as
chronic kidney disease (CKD), cirrhosis, and pulmonary fibrosis
(Friedman et al., 2013). Since a strong correlation between
tubulo-interstitial injury and decreased glomerular filtration rate
was first described, many researchers have sought the origin
of scar-forming cells, i.e., myofibroblasts that are fibroblast-
like cells with contractile properties, in the renal interstitium
(Quaggin and Kapus, 2011; Boor and Floege, 2012). Using genetic
lineage tracing, various cellular sources have been postulated
as the origins of myofibroblasts, including pericytes, resident
fibroblasts, tubular cells, endothelial cells, fibrocytes, and bone
marrow-derived cells, but exact contributions of the sources to
renal fibrosis still remain under debate (summarized in Table 2)
(Quaggin and Kapus, 2011; Mack and Yanagita, 2014).
A possible direct link between the loss of Epo production
and progression of fibrosis was first proposed in 1997 (Maxwell
et al., 1997). Maxwell et al. showed that REPs, which are tagged
by integrated SV40 T antigen cDNA in the Epo gene locus,
turn into desmin-positive myofibroblasts following ureteral
obstruction injury, and that the number of T-antigen-expressing
cells decreases to less than 5% of control kidneys in 9 days after
the obstruction (Maxwell et al., 1997). Interestingly, tamoxifen,
a selective estrogen receptor modulator, is found to improve the
Epo-producing ability of myofibroblasts (Asada et al., 2011).
To better understand the contribution of REPs to renal
fibrosis and the link between fibrosis and anemia, ISAM have
been utilized as the most efficient reporter mouse model for
the Epo-producing ability. The Epo-producing ability of REPs
is lost in kidneys within 24 h after ureteral obstruction, and
strong α-smooth muscle actin (αSMA) expression is observed
in REPs from 2 days following ureteral obstruction onward
(Figure 4). These results indicate that the renal fibrogenic milieu
strongly represses Epo gene transcription in REPs during their
myofibroblast transformation process (Souma et al., 2013). Gene
expression analyses of isolated MF-REPs show that MF-REPs
produce inflammatory cytokines, chemokines, and extracellular
matrix; all of which drive renal fibrosis. Consistent with the
finding that renal myofibroblasts contribute to the inflammatory
milieu, damage-associated molecular patterns (DAMPs) induce
IL-6 and MCP1 productions in myofibroblasts (Campanholle
et al., 2013). Additionally, the loss of local Epo production might
have deteriorating effects on fibrogenesis and inflammation in
the kidneys, because cytoprotective function of Epo beyond
erythropoiesis has been predicted (Noguchi et al., 2008).
Functional lineage tracing using the EpoCre transgene shows
that the cortical and outer medullary interstitium of ISAM-REC
kidneys are primarily replaced by MF-REPs in unilateral ureteral
obstruction (UUO) model, indicating that REPs are the major
source of the myofibroblasts (Table 2) (Souma et al., 2013). MF-
REPs lose their Epo-producing ability and persist in scar tissues.
These results indicate that the transformation of REPs to MF-
REPs or myofibroblasts directly links both fibrosis and anemia.
Interestingly, the product of the hemoglobin (Hb) concentration
times the Epo concentration in the peripheral blood of patients
with diabetic nephropathy correlates well with the stages of
diabetic nephropathy and predicts future chronic renal failure
in overt diabetic nephropathy (Inomata et al., 1997). Although
confirmation of this argument waits for larger studies, we surmise
that Epo would be a good biomarker to estimate the severity
of interstitial injury and to predict the prognosis of damaged
kidneys based on the short half-life (4–8 h) of Epo (Jelkmann,
2002).
One aspect that makes the determination of the origins
of myofibroblasts difficult is the complexity regarding the
identity of the interstitial cells, i.e., pericytes, fibroblasts, and
REPs. It has been shown that FoxD1-tagged pericytes are
the major source of renal myofibroblasts (Humphreys et al.,
2010), whereas another groups argue that resident fibroblasts
are the major source of renal myofibroblasts (Table 2) (Asada
et al., 2011; LeBleu et al., 2013). As mentioned above, we
found that REPs are the major source of renal myofibroblasts
through EpoCre-based functional lineage tracing (Souma et al.,
2013). Because these three cell types (pericytes, resident
fibroblasts, and REPs) share similar cellular surface markers
(PDGFRβ and CD73), locations, and morphology, we believe
that these cells are largely overlapping populations. Recently,
Kramann et al. reported that a small subset of pericytes
(Gli1+PDGFRβ+CD73− cells; 0.2% of renal PDGFRβ+ cells),
which displays mesenchymal stem cell features, is the major
contributor of renal fibrosis through rigorous proliferation upon
injury (Kramann et al., 2015). These evidence raise a possibility
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TABLE 2 | Summary of the origins of renal myofibroblasts.
Cell fate tracking method Target cell type Injury model αSMA+ cells References
TUBULAR EPITHELIAL CELLS (EPITHELIAL–MESENCHYMAL TRANSITION, EMT)
γGT-Cre Cortical tubular cells UUO 36% Iwano et al., 2002
γGT-Cre Cortical tubular cells UUO 5% LeBleu et al., 2013
Pax8-rtTA:TetON-Cre All tubular cells TGFβ O/E 0% Koesters et al.,
2010
Ksp-Cre Distal tubular cells UUO 0% Li et al., 2010
Six2-Cre/Hoxb7-Cre All tubular cells UUO 0% Humphreys et al.,
2010
INTERSTITIAL MESENCHYMAL CELLS (FIBROBLASTS/PERICYTES/REPS)
FoxD1-Cre Pericytes, fibroblasts UUO >90% Humphreys et al.,
2010
P0-Cre Fibroblasts UUO 93% Asada et al., 2011
EpoCre REPs UUO >80% Souma et al., 2013
ENDOTHELIAL CELLS (ENDOTHELIAL-MESENCHYMAL TRANSITION, ENDMT)
Tie2-Cre Endothelial cell UUO/STZ/Alport 30–50% Zeisberg et al., 2008
Cdh5-Cre Endothelial cell UUO 10% LeBleu et al., 2013
BONE MARROW-DERIVED CELLS
Fsp1-EGFP, BMT Myeloid cells, fibroblasts UUO 15%** Iwano et al., 2002
Col1a1-GFP, BMT Collagen-producing cells UUO <0.1% Lin et al., 2008
Y chromosome, BMT Bone marrow-derived cells UUO 8.6%* Roufosse et al.,
2006
Y chromosome, BMT Bone marrow-derived cells UIRI Detected Lin et al., 2009
R26-hPAP, BMT Bone marrow-derived cells UIRI 32%** Broekema et al.,
2007
αSMA-RFP, BMT αSMA-positive cells UUO 35% LeBleu et al., 2013
UUO, unilateral ureteral obstruction; UIRI, unilateral ischemia reperfusion injury; STZ, streptozotocin-induced diabetic nephropathy; Alport, Col4a3 knockout mice; O/E, overexpression.
*No collagen I production; **collagen I production; **12% of αSMA-positive cells in normal kidneys were derived from the bone marrow.
that renal myofibroblasts are originated from a Gli1+ subset
of EpoCre-tagged REPs, and this hypothesis waits for future
confirmation.
Plasticity of REPs
Some clinical and experimental reports have shown that renal
structural damage, including fibrosis, is reversible (Zeisberg et al.,
2003; Fioretto et al., 2006). Clinical observations have shown
that more than 10% of patients on dialysis become anemia
free and rHuEpo independent (Takeda et al., 2002; Kuo et al.,
2005; Schwartz et al., 2005). These lines of evidence suggest that
MF-REPs retain functional reversibility even in ESRD. Indeed,
a short-term reversible UUO model demonstrates that MF-
REPs regain their physiological characteristics, morphology, and
Epo-producing ability following disease resolution (Figure 5)
(Souma et al., 2013). Furthermore, dexamethasone facilitates
this reversion, possibly through enhancing the resolution of
inflammation in injured kidneys (Souma et al., 2013). These
results indicate that REPs possess plasticity in response to
environmental cues. Consistent with this observation, hepatic
myofibroblasts can revert to their normal cellular character
(hepatic stellate cells) during the regression of fibrosis (Kisseleva
et al., 2012).
Environmental Cues for Myofibroblast
Transformation
A genome-wide transcriptome analysis of sham-treated kidneys,
obstructed kidneys, and recovering kidneys indicates that the
atherosclerotic and acute phase response signals are the top two
up-regulated pathways and that valine, leucine, and isoleucine
degradation and fatty acid metabolisms are the top two down-
regulated pathways (Souma et al., 2013). Recent transcriptome
analyses using kidney samples from human CKD patients reveals
that the gene expressions of fatty acid metabolism are decreased
and inflammatory signaling is increased in kidney diseases (Kang
et al., 2015). Based on the fact that metabolic intermediates
play an important role in gene regulation, it is of great interest
to determine whether deranged fatty acid metabolism would
affect Epo production and whether correcting the metabolism,
e.g., by PPARα activation (Kang et al., 2015), would restore
Epo-producing ability of MF-REPs.
Uremic toxins are a group of compounds that are normally
excreted by healthy kidneys, but accumulate upon kidney
injuries. Of the toxins, indoxyl sulfates cause renal inflammation
and repress Epo production by decreasing HIF-α accumulation
in response to hypoxic stimuli (Chiang et al., 2011), and
the NO antagonist NG-monomethyl-L-arginine (L-NMMA)
represses Epo gene transcription through GATA2 upregulation
Frontiers in Physiology | www.frontiersin.org 6 June 2015 | Volume 6 | Article 167
Souma et al. Renal Epo-producing cells
FIGURE 4 | Myofibroblast transformation of REPs. Immunohistochemical
detection of myofibroblasts with αSMA antibody (red) in ureteral obstructed
kidney of ISAM. EpoGFP-positive REPs (green) transform into myofibroblasts
(MF-REPs) upon kidney injury induced by ureteral obstruction for 3 days. Blue:
DAPI for nuclear staining. EpoGFP protein expression does not reflect ongoing
Epo gene transcription due to its longer half-life. EpoGFP mRNA expression is
immediately silenced by urinary obstruction (Souma et al., 2013). Scale bar,
100µm.
(Tarumoto et al., 2000). These results further emphasize the
importance of correcting the unbalanced microenvironment in
injured kidneys.
The TGFβ and NFκB signaling pathways are two major
signaling pathways involved in kidney fibrosis. Of note, TGFβ
but not LPS injection leads to up-regulation of genes for
extracellular matrix, while LPS but not TGFβ injection represses
Epo gene expression. These results support the notion that TGFβ
signaling is the master regulator of the fibrogenic response,
while the inflammatory signals are the primary regulators of Epo
repression (Souma et al., 2013).
Recently, cellular communication upon kidney injuries is
gaining attention, particularly communication between renal
tubular cells and fibroblasts/pericytes (Grgic et al., 2012;
Humphreys et al., 2013), pericytes and endothelial cells (Schrimpf
et al., 2012), and infiltrating leukocytes and resident renal cells
such as distal tubular cells (Fujiu et al., 2011). However, fewer
efforts have been made to decipher the nexus of environmental
cues by quantifying the contribution of each cell type to the
fibrogenic cues. Gene expression analyses of leukocytes isolated
from injured kidneys demonstrate that expressions of TNFα,
TGFβ, and MMP9 are enriched in leukocytes, whereas IL-6
and MMP3 expressions are not, suggesting that the infiltrating
leukocytes and other resident renal cells collaboratively create
deleterious inflammatory microenvironments (Souma et al.,
2013).
FIGURE 5 | The cellular plasticity of REPs governs both fibrosis and
anemia. (A) Schematic diagram of the reversible UUO model. The left ureter is
obstructed by a vascular clip for 2 days and then re-opened afterwards. (B)
The inverse relationship between EpoGFP and αSMA mRNA expression in
whole kidneys of ISAM during reversible UUO treatment. (C) Schematic
summary showing the plasticity of REPs. MF-REPs produce extracellular
matrix (ECM) and inflammatory cytokines in injured kidneys through SMAD and
NFκB signaling cascades. After the resolution of environmental cues,
MF-REPs revert to their original and physiological Epo-producing phenotype.
Switching between ON-REPs and OFF-REPs is determined in a
hypoxia-dependent manner via HIF2α activation.
Epigenetic alterations, including DNA methylation, play
an important role in cellular transformation. TGFβ-mediated
activation of DNA methyl transferase 1 (DNMT1) has been
shown to fundamentally regulate the perpetuation of fibrosis
(Bechtel et al., 2010), and DNMT1 (primarily catalyzes
maintenance methylation) and DNMT3b (primarily catalyzes de
novo methylation) expression is increased in MF-REPs (Souma
et al., 2013). Interestingly, the Epo gene locus is highly methylated
in cell lines lacking Epo-producing abilities, indicating the
importance of DNA methylation for the epigenetic silencing of
Epo gene expression (Yin and Blanchard, 2000). Thus, one would
be easy to surmise that the sustained activation of inflammatory
and fibrogenic signaling may alter the epigenetic code of REPs
and limit the potential of reversing MF-REPs to their original
state.
Effect of Hypoxia on Epo Production and
Kidney Diseases
Kidney injuries and subsequent fibrosis disrupt oxygen delivery
through vascular rarefactions and excessive extracellular matrix
accumulation. Increased oxygen demands also cause kidney cells
to be vulnerable to hypoxia. Renal anemia further compromises
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the delivery of oxygen, and the anemic hypoxia has been
suggested to promote kidney diseases (Nangaku, 2006). Because
HIFs are the major regulators of hypoxic adaptation, augmenting
HIF signaling has been attempted to treat kidney diseases
(Miyata et al., 2013). A clinical trial has been reported that
the pharmacological activation of HIF signaling successfully
augmented Epo production in ESRD (Bernhardt et al., 2010),
underscoring the feasibility of this therapeutic strategy. Actually,
REP-specific knockout of PHD2 in mice induces Epo production
both in healthy and fibrotic kidneys through HIF2α activation
(Souma et al., in press).
Genetic activation of HIF signaling in podocytes and/or
proximal tubular cells results in the worsening of kidney diseases
(Ding et al., 2006; Higgins et al., 2007), whereas deletions of
HIF signaling in myeloid cells, endothelial cells, and/or whole
body (Kobayashi et al., 2012; Kapitsinou et al., 2014) result
in improvement of renal inflammation and fibrosis. Adequacy
of hypoxia signaling upon kidney injuries has been questioned
recently. Immunohistochemical analyses of kidneys in a rodent
AKI model have revealed that HIF1α expression is impaired
in proximal tubular cells (Fahling et al., 2013). Similarly,
EpoGFP expression in ISAM is repressed by ureteral obstruction
despite the presence of severe anemia (Souma et al., 2013).
Furthermore, the successful augmentation of Epo production in
diseased kidneys by PHD inhibitors implies that the primary
cause of Epo insufficiency is the inappropriately high PHD
activity in diseased kidneys, despite a severely hypoxic milieu
(Bernhardt et al., 2010). Collectively, we posit that the response
to hypoxia is impaired or insufficient upon kidney injury through
inappropriately high PHD activity (Souma et al., in press).
Epo production is inappropriately repressed despite the
presence of severe hypoxia in injured kidneys. Interestingly,
TNFα-treated rodents show decreased Epo-producing ability
under hypoxic or anemic conditions (Nakano et al., 2004).
Consistent with this observation, inflammatory cytokines
elicited in damaged kidneys repress the Epo-producing ability,
emphasizing the important effect of sterile inflammation on
repressing the Epo-producing ability of REPs (Souma et al.,
2013). Considering these data, we posit that inflammatory signals
redistribute cellular oxygen levels and activate PHDs in severely
hypoxic kidneys, resulting inHIF2α degradation and impairment
of the Epo gene expression (Souma et al., in press).
Perspectives
We propose that identifying signals that restore physiological
characteristics of REPs in fibrotic kidneys will open a new
avenue for treating CKD. To accomplish this goal, several
barriers must be overcome. One of the highest barriers is the
difficulty in handling REPs. To screen candidate pathway to
treat CKD, a good readout that reflects both diseased and
recovered states of kidneys is necessary. For tubular cells, KIM-
1 and NGAL (Paragas et al., 2011; Humphreys et al., 2013)
are the representative readouts for the injured state and are
available in clinics. For myofibroblast activation, αSMA and
collagen expression is currently used for monitoring fibrogenic
activity. However, these markers are not perfect for testing
whether cells regain their original character upon treatment. The
Epo-producing ability is the important physiological feature of
renal fibroblast-like cells, and its loss is the hallmark of renal
myofibroblasts. Thus, developing a methodology to culture REPs
ex vivo and to monitor their Epo-producing ability by reporter
genes would provide an opportunity to perform high-throughput
screening to identify novel target signals to restore MF-REPs to
normal REPs.
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